EASYTRAK 3 Downsize Lead

Inclusion Criteria: * Must be indicated for a Guidant CRT-P or CRT-D device * Creatinine \< 2.5 mg/dL obtained no more than two weeks prior to enrollment * Age 18 or above, or of legal age to give informed consent specific to state and national law * Willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical investigation at an approved clinical investigation center and at the intervals defined by this protocol * Geographically stable residents who are available for follow-up Exclusion Criteria: * Have a known hypersensitivity to a 0.5 mg nominal dose of dexamethasone acetate * Have or had previous cardiac resynchronization therapy, a coronary venous pace/sense lead or attempted LV lead placement * Have pre-existing cardioversion/defibrillation leads or right ventricular pacing leads other than those specified in the investigational plan (unless the investigator intends to replace them with permitted cardioversion/defibrillation leads) * Currently requiring dialysis * Have had a myocardial infarct, unstable angina, percutaneous coronary intervention, or coronary artery bypass graft during the preceding 30 days prior to enrollment * Have hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis) * Documented life expectancy of less than six months or expected to undergo heart transplant within the next six months * Enrolled or participating in any concurrent study, including drug investigations, without Guidant written approval, that may confound the results of this study * Have a pre-existing unipolar pacemaker that will not be explanted/abandoned * Have a mechanical tricuspid heart valve * Women who are pregnant or plan to become pregnant. Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment.